Hansen Medical Announces Closing of Equity Financing
09 8월 2013 - 5:30AM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that it has closed the
private placement announced on July 31, 2013, through which
approximately 28.5 million shares of the Company's common stock
were purchased by Oracle Investment Management, leading medical
device executive Jack W. Schuler, certain members of the Company's
Board of Directors, and other existing and new shareholders,
including several former healthcare executives. Gross proceeds of
the private placement of the shares totaled approximately $35
million, which will be used to support Hansen Medical's efforts to
commercialize the Magellan™ Robotic System, drive further adoption
of the Sensei® Robotic System and strengthen operations across the
Company.
As previously announced, Hansen Medical also issued warrants
exercisable for approximately 34 million shares of the Company's
common stock to such investors, with a purchase price of $0.125 for
each warrant, totaling an additional $4 million of proceeds. Total
gross proceeds to the Company from the sale of common stock and
warrants equaled approximately $39 million. The warrants, if
exercised, could yield the Company additional proceeds of up to $54
million, bringing the total investment to approximately $93
million. All warrants have a two year term and are not
transferable. Under the terms of the agreement, each investor has
agreed to a lockup such that they will not buy (other than through
exercise of the warrants) or sell any shares of common stock for a
one year period following the closing date.
As previously announced, today the Company's Board of Directors
increased the number of directors of the Company from nine to ten
persons, and appointed Mr. Schuler to the Company's Board of
Directors. The appointment of Mr. Schuler was provided as part of
the private placement.
The securities offered have not been registered under the
Securities Exchange Act of 1933, as amended, and may not be offered
or sold in the U.S., absent registration or an applicable exemption
from registration requirements.
Piper Jaffray served as exclusive placement agent in connection
with the private placement.
Forward-Looking Statements This press
release contains forward-looking statements regarding, among other
things, statements relating to goals, plans, objectives, milestones
and future events including the closing of the transaction. All
statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements,
including statements containing the words "plan," "expects,"
"potential," "believes," "goal," "estimate," "anticipates," and
similar words. These statements are based on the current estimates
and assumptions of our management as of the date of this press
release and are subject to risks, uncertainties, changes in
circumstances and other factors that may cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Important
factors that could cause actual results to differ materially from
those indicated by such forward-looking statements include, among
others: engineering, regulatory, manufacturing, sales and customer
service challenges in developing new products and entering new
markets; the commercial viability of our products in the
electrophysiology and vascular markets; potential safety and
regulatory issues that could slow or suspend our sales; the effect
of economic conditions on capital spending by our potential
customers; the uncertain timelines for the sales cycle for newly
introduced products; the rate of adoption of our systems and the
rate of use of our catheters; the scope and validity of
intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully
described in the "Risk Factors" section of our Quarterly Report on
Form 10-Q for the quarter ended March 31, 2013 filed with the SEC
on May 10, 2013 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release.
We undertake no obligation to revise or update information herein
to reflect events or circumstances in the future, even if new
information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei, Artisan, Artisan Extend and Lynx are registered
trademarks, and Magellan is a trademark of Hansen Medical, Inc. in
the United States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024